Welcome to our dedicated page for Viridian Therapeutics news (Ticker: $VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Viridian Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Viridian Therapeutics's position in the market.
News
Rhea-AI Summary
Viridian Therapeutics, Inc. (VRDN) will present at the 42nd Annual J.P. Morgan Healthcare Conference, discussing corporate priorities and potential best-in-class medicines for serious and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
-
Rhea-AI Summary
Viridian Therapeutics, Inc. (VRDN) selects VRDN-003 as its lead subcutaneous program for thyroid eye disease (TED) with an extended half-life of 40-50 days, supporting a potential best-in-class, low-volume, less frequent, self-administered therapy. Pivotal clinical development expected to initiate mid-2024 pending regulatory alignment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.52%
Tags
-
Rhea-AI Summary
Viridian Therapeutics, Inc. (VRDN) to participate in fireside chat at 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
News
Rhea-AI Summary
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced the continuation of THRIVE and THRIVE-2 clinical trials for thyroid eye disease patients, expected delivery of topline clinical results in 2024. The company also revealed the advancement of a novel preclinical portfolio of FcRn inhibitors for autoimmune diseases, and the private placement of approximately $185 million to fund pipeline development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.79%
Tags
-
Rhea-AI Summary
Viridian Therapeutics, Inc. (NASDAQ: VRDN) to participate in fireside chat at Jefferies London Healthcare Conference, offering potential best-in-class medicines for serious and rare diseases. Senior management to present at 4:00 p.m. GMT in London, UK, with live webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.54%
Tags
-
Rhea-AI Summary
Viridian Therapeutics, Inc. will present clinical and preclinical data on its pipeline candidates for the treatment of thyroid eye disease (TED) at the AAO 2023 Annual Meeting. The company will highlight VRDN-001, a full antagonist antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), including preliminary clinical results from a Phase 1/2 study. VRDN-001 is currently in Phase 3 clinical studies for active and chronic TED. Viridian will also present preclinical data for VRDN-003, a half-life extended antibody targeting IGF-1R. VRDN-003 is in a Phase 1 clinical study in healthy volunteers. The company expects to select its lead subcutaneous IGF-1R program by year end 2023 and release VRDN-001 Phase 3 topline results in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.88%
Tags
Rhea-AI Summary
Viridian Therapeutics appoints Stephen Mahoney as President and CEO. The company remains on track with its thyroid eye disease programs and expects to select a subcutaneous program by year-end 2023. They also disclose a portfolio of FcRn inhibitors for autoimmune diseases. A private placement will provide $185 million in funding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
-
Rhea-AI Summary
Viridian Therapeutics and Ypsomed AG have signed a supply agreement for Ypsomed's YpsoMate 2.25 autoinjector pen device. The device will be customized and supplied to support Viridian's development of subcutaneous therapy candidates for the treatment of thyroid eye disease (TED). This agreement will potentially expand the TED medicines market and offer more convenience to caregivers and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.57%
Tags
-
Rhea-AI Summary
Sarah Gheuens, CMO and Head of R&D of Agios Pharmaceuticals, joins Viridian Therapeutics' Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
Rhea-AI Summary
Viridian Therapeutics announces presentations on pipeline candidates for thyroid eye disease at upcoming medical meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
Viridian Therapeutics, Inc.
Nasdaq:VRDN
VRDN Rankings
VRDN Stock Data
930.53M
47.94M
1.02%
100.99%
15.09%
Medical Laboratories
Health Care and Social Assistance
United States of America
WALTHAM
About VRDN
miragen therapeutics, inc., (nasdaq: mgen), is a biopharmaceutical company discovering and developing innovative microrna (mirna)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. the company leverages in-house expertise in mirna biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. at miragen, we recognize the importance of creating strategic relationships within the biotech and pharmaceutical industries and with academic institutions globally. this collaborative approach is making important contributions in our efforts to create mirna-targeting therapies. miragen’s areas of focus include hematological malignancies, pathological fibrosis, neuro-degeneration, and cardiovascular disease. in 2011, the company formed a strategic partnership with servier, a privately-run, french research